Helga Witt-Sullivan

837 total citations
9 papers, 576 citations indexed

About

Helga Witt-Sullivan is a scholar working on Epidemiology, Hepatology and Infectious Diseases. According to data from OpenAlex, Helga Witt-Sullivan has authored 9 papers receiving a total of 576 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Epidemiology, 8 papers in Hepatology and 1 paper in Infectious Diseases. Recurrent topics in Helga Witt-Sullivan's work include Liver Disease Diagnosis and Treatment (8 papers), Hepatitis C virus research (5 papers) and Hepatitis B Virus Studies (3 papers). Helga Witt-Sullivan is often cited by papers focused on Liver Disease Diagnosis and Treatment (8 papers), Hepatitis C virus research (5 papers) and Hepatitis B Virus Studies (3 papers). Helga Witt-Sullivan collaborates with scholars based in Canada and United States. Helga Witt-Sullivan's co-authors include Cameron N. Ghent, Ruth Milner, Ian R. Wanless, Laurence M. Blendis, Gerald Y. Minuk, Lawrence Worobetz, Robert J. Bailey, E. Jenny Heathcote, Urs P. Steinbrecher and Lloyd R. Sutherland and has published in prestigious journals such as SHILAP Revista de lepidopterología, Hepatology and Alimentary Pharmacology & Therapeutics.

In The Last Decade

Helga Witt-Sullivan

9 papers receiving 556 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Helga Witt-Sullivan Canada 6 533 465 208 87 45 9 576
I. Carderi Italy 9 328 0.6× 275 0.6× 204 1.0× 103 1.2× 52 1.2× 12 431
Greta Pells United Kingdom 3 436 0.8× 338 0.7× 252 1.2× 66 0.8× 76 1.7× 7 466
A Bernardos Spain 15 373 0.7× 253 0.5× 314 1.5× 54 0.6× 27 0.6× 24 574
Rupert Abdalian Canada 6 408 0.8× 299 0.6× 330 1.6× 51 0.6× 151 3.4× 8 543
M Orsini Italy 3 230 0.4× 231 0.5× 102 0.5× 42 0.5× 97 2.2× 3 409
Horacio L. Rodriguez-Rilo United States 7 244 0.5× 196 0.4× 199 1.0× 28 0.3× 73 1.6× 8 346
D. Caroli Italy 6 289 0.5× 256 0.6× 179 0.9× 34 0.4× 62 1.4× 13 348
Henk van Buuren Netherlands 4 249 0.5× 269 0.6× 255 1.2× 48 0.6× 49 1.1× 6 389
Ayman Alsebaey Egypt 13 249 0.5× 204 0.4× 126 0.6× 30 0.3× 47 1.0× 38 354
Xavier Causse France 8 272 0.5× 266 0.6× 62 0.3× 15 0.2× 32 0.7× 19 365

Countries citing papers authored by Helga Witt-Sullivan

Since Specialization
Citations

This map shows the geographic impact of Helga Witt-Sullivan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Helga Witt-Sullivan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Helga Witt-Sullivan more than expected).

Fields of papers citing papers by Helga Witt-Sullivan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Helga Witt-Sullivan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Helga Witt-Sullivan. The network helps show where Helga Witt-Sullivan may publish in the future.

Co-authorship network of co-authors of Helga Witt-Sullivan

This figure shows the co-authorship network connecting the top 25 collaborators of Helga Witt-Sullivan. A scholar is included among the top collaborators of Helga Witt-Sullivan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Helga Witt-Sullivan. Helga Witt-Sullivan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Marotta, Paul, Robert J. Bailey, Magdy Elkashab, et al.. (2016). Real-world effectiveness of peginterferon α-2b plus ribavirin in a Canadian cohort of treatment-naïve chronic hepatitis C patients with genotypes 2 or 3: results of the PoWer and RediPEN studies. European Journal of Clinical Microbiology & Infectious Diseases. 35(4). 597–609. 1 indexed citations
2.
3.
Yoshida, Eric M., Morris Sherman, Vincent G. Bain, et al.. (2009). Retreatment with Pegylated Interferon Alpha-2a and Ribavirin in Patients with Chronic Hepatitis C Who Have Relapsed or Not Responded to a First Course of Pegylated Interferon-Based Therapy. SHILAP Revista de lepidopterología. 23(3). 180–184. 14 indexed citations
4.
Bain, Vincent G., Shoei‐Sheng Lee, Kevork Peltekian, et al.. (2008). Clinical trial: exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alfa‐2a plus ribavirin. Alimentary Pharmacology & Therapeutics. 28(1). 43–50. 24 indexed citations
5.
Zandieh, Iman, Victor Wong, John M. Howard, et al.. (2008). The Use of Budesonide in the Treatment of Autoimmune Hepatitis in Canada. SHILAP Revista de lepidopterología. 22(4). 388–392. 40 indexed citations
6.
Collier, Jane, Paul A. Adams, Cameron N. Ghent, et al.. (2000). Long Term Follow-Up of Patients with Chronic Hepatitis C Treated with Alpha Interferon. SHILAP Revista de lepidopterología. 14(suppl b). 77B–81B. 4 indexed citations
7.
Heathcote, E. Jenny, Karen Cauch‐Dudek, Valery Walker, et al.. (1994). The canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology. 19(5). 1149–1156. 342 indexed citations
8.
Jacobson, Kevan & Helga Witt-Sullivan. (1992). Interpreting Abnormalities in Routine Liver Biochemistry: How to identify patterns in test results.. Canadian Family Physician. 38(8). 561–566. 2 indexed citations
9.
Witt-Sullivan, Helga, Jenny Heathcote, Laurence M. Blendis, et al.. (1990). The Demography of Primary Biliary Cirrhosis in Ontario, Canada. Hepatology. 12(1). 98–105. 140 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by I. Carderi Breakdown of academic impact, for papers by Greta Pells Breakdown of academic impact, for papers by A Bernardos Breakdown of academic impact, for papers by Rupert Abdalian Breakdown of academic impact, for papers by M Orsini Breakdown of academic impact, for papers by Horacio L. Rodriguez-Rilo Breakdown of academic impact, for papers by D. Caroli Breakdown of academic impact, for papers by Henk van Buuren Breakdown of academic impact, for papers by Ayman Alsebaey Breakdown of academic impact, for papers by Xavier Causse
Rankless by CCL
2026